OphRx Overview
OphRx is developing eye drops based on noninvasive drug delivery that utilize lyotropic liquid crystals as an alternative to current delivery modalities, such as intra-vitreal injections, used to treat diseases at the back of the eye. This platform technology can also be used for front-of-the-eye treatments. OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet AMD; and OPH-100, a treatment for DES. OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.
Cumulative Funding Raised Over Time ($)
$1.0MJan 2014
Latest News
growth-positive
BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert
BioLight Life Sciences Ltd. has announced successful results from its Phase 1/2a clinical trial for its glaucoma insert VS101 (Eye-D latanoprost insert). The trial demonstrated the inserts ability to lower intraocular pressure for a 12-week period with a favourable safety profile. The insert is designed to provide sustained intraocular pressure-lowering for patients who have difficulty taking their prescribed eye drops for the treatment of glaucoma on a daily basis. The trial results comprise data from 77 glaucoma patients collected from 19 clinical centres across the United States.
Customers
growth-positive
When size matters: Tiny innovations for a better world
Yissum Research Development Company, the technology transfer arm of Hebrew University of Jerusalem, showcased breakthrough nanotechnologies at the Innovations in Advanced Materials conference. The company announced the establishment of a new fund to support nanotech and advanced materials projects. Several early-stage technologies were presented, including a cost-effective method to break down plastic waste, a method for inkjet printing sensors onto large areas, and a nanoparticle targeted drug delivery system. Eight startups founded by Yissum in 2015 have raised a total of $14 million. The article highlights the potential impact of these technologies in various industries.
Investment
growth-positive
Conference to showcase Hebrew University nanotech
Yissum Research Development Company, based on research at the Hebrew Universitys Center for Nanoscience and Nanotechnology, has had an impressive year in the commercialization of nanotechnology research. They have filed 86 patent applications, had 29 patents approved, and signed 16 licensing agreements. Additionally, they have established eight new start-up companies based on research performed at the Hebrew Universitys Center for Nanoscience and Nanotechnology. Yissum CEO Yaacov Michlin highlights the acquisition of Qlight Nanotech by Merck KGaA as a notable achievement. Yissum is now seeking commercial partners for the further development of their patented technologies in plastic waste degradation and inkjet printing of sensors.
PartnersInvestment
growth-positive
Bio Light's IOPtiMate[TM] System Receives Regulatory Approval in Canada
Bio Light Israeli Life Sciences Investments Ltd. has received approval from the Canadian Medical Devices Bureau to commercialize its IOPtiMate system for the treatment of glaucoma in Canada. The system uses a CO2 laser-assisted procedure to reduce intraocular pressure and provides a safer alternative to current glaucoma surgeries. Bio Light plans to market the system to physicians and medical centers in Asia and Europe. The company has already made sales in Hong Kong, Poland, Hungary, Romania, Peru, and Portugal, with distribution agreements being negotiated in other countries. Bio Light recently signed a joint-financing agreement with two venture capital firms to support global commercialization and regulatory approval in the US. The approval in Canada will allow the company to initiate commercial activity in the country.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1M |
| Last funding | $1M |
| Stage | Seed |
| Rounds | 1 |
| Investors | 4 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | bio-light.co.il/ophrx-2/ |
Locations
Kiryat Atidim, Tel Aviv-Yafo, Israel
Photos & Videos
No files yet
OphRx Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesNanomaterialsTags (13)
healthcare-providersclinicsdoctorstopical-treatmentnanotechnologypharmaceuticalsophthalmologyeye-diseasesnon-invasivepharma-companiesglaucomamedical-technologiesdrug-deliveryGeographic Markets
GlobalOphRx Financials
$1M
Total funding
Undisclosed
Capital raised
$1M
Last funding
Seed
Funding stage
1
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$1.0MJan 2014
Private Equity Funding
Seed
Jan 2014
$1M
BIOLIGHT Life Sciences, Kremer & Lieberman groups, XLVision Sciences, Integra Holdings
OphRx Lifecycle
Cumulative Funding Raised Over Time
$1.0MJan 2014
All Events
Seed
Jan 2014
$1M
BIOLIGHT Life Sciences, Kremer & Lieberman groups, XLVision Sciences, Integra Holdings
OphRx News
4 articles
growth-positive
BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert
BioLight Life Sciences Ltd. has announced successful results from its Phase 1/2a clinical trial for its glaucoma insert VS101 (Eye-D latanoprost insert). The trial demonstrated the inserts ability to lower intraocular pressure for a 12-week period with a favourable safety profile. The insert is designed to provide sustained intraocular pressure-lowering for patients who have difficulty taking their prescribed eye drops for the treatment of glaucoma on a daily basis. The trial results comprise data from 77 glaucoma patients collected from 19 clinical centres across the United States.
Customers
growth-positive
When size matters: Tiny innovations for a better world
Yissum Research Development Company, the technology transfer arm of Hebrew University of Jerusalem, showcased breakthrough nanotechnologies at the Innovations in Advanced Materials conference. The company announced the establishment of a new fund to support nanotech and advanced materials projects. Several early-stage technologies were presented, including a cost-effective method to break down plastic waste, a method for inkjet printing sensors onto large areas, and a nanoparticle targeted drug delivery system. Eight startups founded by Yissum in 2015 have raised a total of $14 million. The article highlights the potential impact of these technologies in various industries.
Investment
growth-positive
Conference to showcase Hebrew University nanotech
Yissum Research Development Company, based on research at the Hebrew Universitys Center for Nanoscience and Nanotechnology, has had an impressive year in the commercialization of nanotechnology research. They have filed 86 patent applications, had 29 patents approved, and signed 16 licensing agreements. Additionally, they have established eight new start-up companies based on research performed at the Hebrew Universitys Center for Nanoscience and Nanotechnology. Yissum CEO Yaacov Michlin highlights the acquisition of Qlight Nanotech by Merck KGaA as a notable achievement. Yissum is now seeking commercial partners for the further development of their patented technologies in plastic waste degradation and inkjet printing of sensors.
PartnersInvestment
growth-positive
Bio Light's IOPtiMate[TM] System Receives Regulatory Approval in Canada
Bio Light Israeli Life Sciences Investments Ltd. has received approval from the Canadian Medical Devices Bureau to commercialize its IOPtiMate system for the treatment of glaucoma in Canada. The system uses a CO2 laser-assisted procedure to reduce intraocular pressure and provides a safer alternative to current glaucoma surgeries. Bio Light plans to market the system to physicians and medical centers in Asia and Europe. The company has already made sales in Hong Kong, Poland, Hungary, Romania, Peru, and Portugal, with distribution agreements being negotiated in other countries. Bio Light recently signed a joint-financing agreement with two venture capital firms to support global commercialization and regulatory approval in the US. The approval in Canada will allow the company to initiate commercial activity in the country.
Customers
OphRx Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
OphRx Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515226702 |
| Crunchbase | ophrx |
| Phone | +972732753400 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-06-06T00:00:00.000Z |
| Created | 2016-05-02T00:00:00.000Z |